Key result
This review discusses future strategies, including new drugs, devices, and gene therapy, for the treatment of diastolic heart failure.
This review highlights the need for novel therapeutic strategies, including drugs, devices, and gene therapy, for the management of diastolic heart failure.
Diastolic HF lacks proven therapies; leaves open whether new drugs, devices, or gene therapy will improve outcomes.
It is estimated that 30% to 50% of heart failure patients have preserved systolic left ventricular (LV) function, often referred to as diastolic heart failure (DHF). Mortality is high in this patient population, and morbidity and rate of hospitalization are similar to those of patients with systolic heart failure. The management of patients with diastolic heart failure is essentially empirical, limited, and disappointing. New drugs, devices, and gene therapy based treatment options are currently under investigation. In this review, future strategies for the treatment of diastolic heart failure are discussed.
No takes yet. Share an insight, caveat, or question.
Feld et al. (2006) conducted a review in Diastolic heart failure. Future strategies (new drugs, devices, and gene therapy) was evaluated. This review discusses future strategies, including new drugs, devices, and gene therapy, for the treatment of diastolic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: